Anika Therapeutics (ANIK) EV to EBITDA (2010 - 2026)

Anika Therapeutics (ANIK) has reported EV to EBITDA for 17 consecutive years, with 53.28 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 395.28% year-over-year to 53.28 in Q2 2026; TTM through Jun 2026 was 30.73, a 276.92% decrease from a year earlier, with the FY2025 full-year figure at 4.73, up 84.73% from the prior year.
• EV to EBITDA was 53.28 for Q2 2026 at Anika Therapeutics, up from 23.12 in the prior quarter.
• Over five years, EV to EBITDA peaked at 80.96 in Q4 2025 and troughed at 3360.7 in Q3 2024.
• A 5-year average of 226.04 and a median of 28.82 in 2023 frame the typical range for EV to EBITDA.
• Across the five-year window, EV to EBITDA slumped 15310.43% in 2024 and surged 395.28% in 2026, its largest moves.
• Over 5 years, EV to EBITDA stood at 19.02 in 2022, then tumbled by 49.53% to 9.6 in 2023, then slumped by 2435.9% to 224.2 in 2024, then surged by 136.11% to 80.96 in 2025, then tumbled by 34.2% to 53.28 in 2026.
• The last three EV to EBITDA figures came in at 53.28 (Q2 2026), 23.12 (Q1 2026), and 80.96 (Q4 2025), per Business Quant data.